Likelihood of Approval and Phase Transition Success Rate Model – Bevacizumab in Hepatocellular Carcinoma

Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – Bevacizumab in Hepatocellular Carcinoma report and make more profitable business decisions.

This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.

Bevacizumab in Hepatocellular Carcinoma Drug Details:

Bevacizumab (Avastin) is a recombinant humanized monoclonal IgG1 antibody. It is formulated as solution, concentrate solution for intravenous route of administration. Avastin in combination with xeloda or paclitaxel is indicated for the treatment of metastatic breast cancer. In combination with cisplatin (or carboplatin) and etoposide, bevacizumab is indicated for the treatment of small-cell lung cancer. Avastin is used for the treatment of metastatic colorectal cancer, non-squamous non-small cell lung cancer (with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease) and glioblastoma, with interferon alfa. Avastin in combination with carboplatin and gemcitabine, is indicated for the treatment of patients with recurrent, platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer, malignant glioma. It is also indicated for the treatment of persistent, recurrent or metastatic cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan. In combination with paclitaxel it is used for the treatment of platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.  It is also indicated for the treatment of cervical cancer with standard chemotherapy (paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy). Avastin is also indicated in combination with chemotherapy, to treat patients with recurrent ovarian cancer (Advanced Ovarian cancer). Avastin either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, and in combination with atezolizumab for patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy. Avastin in combination with atezolizumab is indicated for the treatment unresectable hepatocellular carcinoma. It is also indicated for the treatment of locally recurrent or metastatic triple negative Breast Cancer (mBC)Bevacizumab (RG435) is under development for the treatment of metastatic hepatocellular carcinoma, non-small cell lung cancer, metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma (first and second line therapy), as first line therapy for epithelial ovarian, fallopian tube, primary peritoneal cancer,  endometrial cancer and hepatocellular carcinoma, locally advanced/metastatic well-differentiated digestive endocrine tumors, malignant mesothelioma, melanoma as first line and second line therapy, nasopharyngeal carcinoma, appendiceal adenocarcinoma, relapsed or refractory neuroblastoma (second line), adjuvant breast cancer (BC) HER2 negative, oligodendroglioma, metastatic breast cancer first and second line therapy, epithelial ovarian, bile duct cancer (first line), endocrine tumors of the gastrointestinal tract, and renal cell carcinoma in Japan. Avastin in combination with Tarceva (erlotinib) is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR)-activating mutations. It is also indicated in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin is indicated for the treatment of patients with recurrent, platinum-resistant epithelial ovarian and non-small cell lung cancer. It is under development for the treatment of recurrent glioblastoma multiforme and malignant pleural mesothelioma and Acute Respiratory Distress Syndrome (ARDS). It is also under development for anal cancer, cervical cancer, vulvar cancer, vaginal cancer and penile cancer.It was also under development for non metastatic bladder cancer, HER2- breast cancer, adjuvant non small cell lung cancer (NSCLC), metastatic liver cancer, chronic lymphocytic leukemia (CLL), intracranial meningioma, urothelial cell carcinoma, neuroendocrine carcinoid carcinoma, locally advanced and/or metastatic pancreatic cancer, cervical cancer, relapsed/refractory multiple myeloma and for diffuse large B-cell lymphoma and as adjuvant therapy for HER2 positive breast cancer, glioblastoma multiforme first line and metastatic rhabdomyosarcoma, metastatic renal cell carcinoma and non-rhabdomyosarcoma soft tissue sarcoma.

Report Coverage

The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.

The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.

Quick View – Bevacizumab LOA Data
Report Segments	· Drug type · Intervention type
Drug Name	· Bevacizumab
Administration Pathway	· Intravenous
Therapeutic Areas	· Oncology| Respiratory
Key Manufacturers	· F. Hoffmann-La Roche Ltd
Drug Development Status	· Marketed

Reasons to Buy

• Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
• Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
• Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
• Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.

Scope

• Drug Details: Drug name, Drug type, Intervention type
• Administration Pathway
• Therapeutic Areas
• Key Manufacturers
• Drug Development Status

This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance.